AIM
CDTX

Alambic Investment Management’s Cidara Therapeutics CDTX Stock Holding History

Alambic Investment Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-651
Closed -$57K – 321
2018
Q3 		$57K Buy
651
+39
+6% +$3.44K 0.05% 268
2018
Q2 		$64K Sell
612
-588
-49% -$55.5K 0.02% 339
2018
Q1 		$96K Buy
+1,200
New +$164K 0.01% 437

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Alambic Investment Management's CDTX Position: Q4 2018 in Review

Alambic Investment Management sold out of Cidara Therapeutics (CDTX) in Q4 2018, closing a stake of 651 shares — an estimated $57K sold.

Alambic Investment Management first reported a position in CDTX in Q1 2018 and held it in 3 quarters. The position peaked at $96K in Q1 2018. 49 funds tracked by Wall St. Rank hold CDTX as of Q4 2018.

  • Alambic Investment Management reported no remaining Cidara Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Alambic Investment Management sold 651 Cidara Therapeutics shares in Q4 2018, an estimated $57K.
  • Alambic Investment Management first reported a position in Cidara Therapeutics in Q1 2018 and held it in 3 quarters.
  • Alambic Investment Management's Cidara Therapeutics position peaked at $96K in Q1 2018.
  • 49 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2018.

Based on Alambic Investment Management's 13F filing for Q4 2018, filed 12 Feb 2019.